Transcript of Tumor (really “GROWTH”) suppressor genes TGF- β COLON E-cadherin STOMACH NF-1,2 NEURAL...
- Slide 1
- Tumor (really GROWTH) suppressor genes TGF- COLON E-cadherin
STOMACH NF-1,2 NEURAL TUMORS APC/ -cadherin GI, MELANOMA SMADs GI
RB RETINOBLASTOMA P53 EVERYTHING!! WT-1 WILMS TUMOR p16 (INK4a) GI,
BREAST BRCA-1,2 BREAST KLF6 PROSTATE
- Slide 2
- TRANSFORMATION & PROGRESSION Self-sufficiency in growth
signals Insensitivity to growth-inhibiting signals Evasion of
apoptosis Limitless replicative potential: Telomerase Angiogenesis
Invasive ability Metastatic ability Defects in DNA repair: Spell
checker
- Slide 3
- Slide 4
- Slide 5
- Evasion of APOPTOSIS BCL-2 Overexpression Seen in B-cell
lymphomas of follicular type t(14;18)(q32;q21),dominant with IgH
genes and overexpression of BCL-2 protein P53 (Pro-apoptic gene) -
Directly activates Bax (Bcl-2 protein) Reduced levels of CD95/Fas
FLIP protein Inhibits Caspase 8 Loss of APAF1(Apoptosis activating
factor-1) Increased IAP (inhibitors of apoptosis)
- Slide 6
- LIMITLESS REPLICATIVE POTENTIAL TELOMERES determine the limited
number of duplications a cell will have! TELOMERASE, present in
>90% of human cancers, changes telomeres so they will have
UNLIMITED replicative potential
- Slide 7
- Slide 8
- TUMOR ANGIOGENESIS Q : How close to a blood vessel must a cell
be? A: 1-2 mm Activation of VEGF and FGF-b Tumor size is regulated
(allowed) by angiogenesis/anti-angiogenesis balance
- Slide 9
- Proteases of tumors can induce production of angiogenic factors
and inhibitors Proteases act on ECM components (E.g. Collagen)
releasing bFGF and VEGF VEGF triggers the NOTCH Pathway
- Slide 10
- INVADE & METASTASIS 1. Invasion of Extracellular Matrix 2.
Vascular Dissemination Invading the Extracellular matrix requires
breaching the basement membrane Intersitial Connective Tissue
Vascular Basement Membrane
- Slide 11
- Invasion of ECM 1. Detachment ("loosening up") of the tumor
cells from each other Down-regulation of E-cadherin and
Beta-catenin reducing cells adherance to each other
- Slide 12
- Invasion of ECM 2. Degradation of ECM, e.g., collagenase, etc.
Break down the basement membrane Proteases MMP (matrix
metalloproteinases) Releasing growth factors (e.g. VEGF) and
angiogenic, growth promoting effects with cleavage of Type IV
collagen for example 3. Attachment to matrix components Breakdown
by MMP allows tumor cell receptors to bind ECM proteins and
stimulate migration E.g. MMP2 cleaves laminin and MMP9 cleaves
collagen IV Change in tumor cell receptor attachment to ECM
proteins Stimulates Migration
- Slide 13
- Invasion of ECM Migration of tumor cells Cytokines ( autocrine
factors) Cleavage of the ECM components (Laminin, collagen) and
growth factors (IGF I, II) that have chemotactic activity Stromal
cells around tumor also produce hepatocyte growth factor-scatter
factor promoting motility
- Slide 14
- Slide 15
- TRANSFORMATION GROWTH BM INVASION ANGIOGENESIS INTRAVASATION
EMBOLIZATION ADHESION EXTRAVASATION METASTATIC GROWTH etc.
- Slide 16
- Vascular Dissemination Following intravasation, clumps of
platelet-tumor aggregates are formed Extravastion of this tumor
emboli at distant sites Attachment to the endothelium Exits through
the basement membrane Followed by migration to lymphoid tissue
using the CD44 adhesion molecule (expressed on T cells) CD44 binds
to hyaluronate allowing migration and towards metastic spread *Most
metastases occur in the first capillary bed available to tumor
- Slide 17
- Other possible mechanisms explaining metastasis: 1. Tumor cell
adhesion molecule ligands are expressed on the endothelial cell of
target tissue Target organ variation in endothelial cell expression
of adhesion molecule ligands 2. Chemokine receptors are expressed
in cancer cells that allowing binding of chemokines expressed at
specific tissues E.g. CXCR4 and CCR7 receptors expressed in breast
cancer cells 3. Chemoattractants E.g. IGF 1, II, can be expressed
at target tissues
- Slide 18
- Breast cancer cells, how do they adapt and make their
environment habitable? - Osteolytic behavior in bone by osteoclasts
Tumor cells PTHRP (parathyroid hormone-related protein) Osteoblasts
RANK ligand Osteoclasts Osteoclasts break down the matrix releasing
growth factors
- Slide 19
- Development of Metastasis One hypothesis suggest why only some
tumors metastasize? Metastasis Signature Multiple abnormalities
taking place in the early stage of development Intrinsic
properties, microenvironment (stroma), angiogenesis, resistance to
immune defenders, and local invasiveness Other hypothesis Rare
clonal variation that develop metastasis
- Slide 20
- DEFECTS IN DNA REPAIR 1. Mismatch Repair 2. Nucleotide Excision
Repair 3. Recombination Repair
- Slide 21
- DNA REPAIR GENE DEFECTS DNA repair is like a spell checker
HNPCC (Hereditary Non-Polyposis Colon Cancer [Lynch]): TGF- , -
catenin, BAX Xeroderma Pigmentosum: UV fixing gene Ataxia
Telangiectasia: ATM gene Bloom Syndrome: defective helicase Fanconi
anemia
- Slide 22
- Hereditary Non-Polyposis Colon Cancer Mismatch Repair
Proofreaders disabled Microsatellite fragments 1 to 6 nucleotide
repeats Creates instability Dna mismatch repair gene affect cell
growth indirectly, through mutations in other genes TGF-beta,
beta-catenin, Bax
- Slide 23
- Xeroderma Pigmentosum UV radiation exposure Pyrimidine dimers
DNA damage with defect in nucleotide excision repair
- Slide 24
- Autosomal Recessive Disorders Defect in DNA repair by
Homologous Recombination Ataxia Telangiactasia neurological
degenerative disorder, exposure to Ionizing radiation Defective ATM
gene Bloom Syndrome - Ionizing radiation resulting in developmental
defects Defect in gene of chromosme 15 encodes helicase dna repair
through homologus recombination Fanconi anemia Chemotherapeutic
agents causing damage Bone-marrow aplasia BRCA1 and BRCA 2 Proteins
take part in homologous recombination repair pathway Mutation of
BRCA2 gene chromosomal breaks & aneuploidy
- Slide 25
- STROMAL MICROENVIRONMENT Cross-Talk between the tumor cells and
ECM E.g. Laminin degradation by MMP2 Stimulates tumor cell motility
E.g. Type IV collagen degradation by MMP9 Release of VEGF Storage
of inactive growth factors in ECM, proteases release the active
form (E.g. PDGF, TGF-beta, bFGF)
- Slide 26
- STROMAL MICROENVIRONMENT Inflammatory Cells and fibroblasts
Cytokines released during inflammation Induce survival and
progression of tumor cells Chemokines Chemotactic properties
Fibroblasts Important role in tumor cells Desmoplastic response,
highly fibrotic, promoting growth
- Slide 27
- Metabolism of Tumors
- Slide 28
- WARBURG EFFECT Otto Warburg, Nobel Prize discovery on the
metabolism of turmors Cancer cells rely on Aerobic Glycolysis,
Warburg Effect, instead of the mitochondrial oxidative
phosphorylation Several Hypothesis 1. During angiogenesis, vessels
are poorly formed, activation of H1F1alpha due to hypoxia increases
expression of enzymes of glycolysis, and vasculature 2. Exposure to
state of continous hypoxia and normoxia 3. Mutations in oncogene
and tumor supressors (p53, RAS, PTEN) stimulate metabolic
changes
- Slide 29
- Metabolic Alterations In addition, tumor cells need to build
and maintain its membrane, proteins, and organelles --- Anabolic
Pathway Lipid, nucleotide, proteins (amino acids), glucose (carbon)
Glutamine Both glycolytic and anabolic pathway
- Slide 30
- PI3K/AKT/Mtor pathway Important in regulating normal cell
functions including amino acid, glucose uptake In tumors, mutation
of tumor supressors and oncogenes - -- Abnormality in pathway can
occur favoring survival and proliferation of tumor cells E.g. PTEN
has a negative regulation of this pathway,
- Slide 31
- Slide 32
- Other tumor supressors that supress this pathway:- Peutz-Jegher
syndrome mutated gene LKB1 ( Liver kinase B1) Limits or regulates
cell growth by AMP-dependent protein kinase mechanism Negative
regulator of mTOR pathway Supression of LKBI (also called STK11)
Increase in anabolic metabolism of cancer cells TuberousSclerosis
mutated genes (TSC1 and TSC2) ----- Negative regulation of
mTOR
- Slide 33
- CHROMOSOME CHANGES in CANCER TRANSLOCATIONS and INVERSIONS
Occur in MOST Lymphomas/Leukemias Occur in MANY (and growing
numbers) of NON-hematologic malignancies also
- Slide 34
- MalignancyTranslocationAffected Genes Chronic myeloid
leukemia(9;22)(q34;q11)Ab1 9q34 bcr 22q11 Acute leukemias (AML and
ALL)(4;11)(q21;q23)AF4 4q21 MLL 11q23 (6;11)(q27;q23)AF6 6q27 MLL
11q23 Burkitt lymphoma(8;14)(q24;q32)c-myc 8q24 IgH 14q32 Mantle
cell lymphoma(11;14)(q13;q32)Cyclin D 11q13 IgH 14q32 Follicular
lymphoma(14;18)(q32;q21)IgH 14q32 bcl-2 18q21 T-cell acute
lymphoblastic leukemia(8;14)(q24;q11)c-myc 8q24 TCR- 14q11
(10;14)(q24;q11)Hox 11 10q24 TCR- 14q11 Ewing
sarcoma(11;22)(q24;q12)Fl-1 11q24 EWS 22q12
- Slide 35
- Translocations ------------- Activate Proto-Oncogenes 2 common
mechanism of translocation: A) Lymphoid Tumors --- Swapping or
movement of segment of chromosome to another chromosome B)
Hematopoietic tumors --- Two chromosomes recombine to form hybrid
fusion genes for production of chimeric proteins
- Slide 36
- Burkitt Lymphoma:- t(8:14) (q24;q32) Translocation at
chromosome 8 (c-MYC) and 14 ( IGH gene) MYC containing segment of
chromosome 8 movement to to chromosome 14q32 at IGH gene
Overexpression of MYC
- Slide 37
- Slide 38
- Follicular Lymphomas:- t(14:18) (q32:q21) Translocation at
chromosome 14 (IGH gene) and 18 (BCL2) Activation of BCL2
- Slide 39
- Chronic Myeloid Leukemia (CML):- t(9;22) (q34;q11)
Translocation at chromosome 9 (ABL gene) and 22 (BCR gene)
- Slide 40
- What is the Philadelphia chromosome? Chromosome 22 that
exchanges portion (reciprocal translocation) of the chromosome with
Chromosome 9 Fusion of two genes BCR-ABL producing protein with
tyrosine kinase activity Found in both CML & ALL (Acute
Lymphoblastic Leukemia)
- Slide 41
- Slide 42
- Ewing Sarcoma Also known as PNET (Primitive neuroectodermal
tumor) T(11:22) (q24;q12) FLI 1 gene and EWSR1 gene Chimeric
protein EWS-FLI 1 Fusion of most genes encode for transcription
factors
- Slide 43
- GENE AMPLIFICATION Amplification of particular chromosomal
regions that contain the oncogenic sequence Hallmark Features:-
Double minutes ---- Small, centric structures or chromatin bodies
of extrachromosomal dna Homogenous staining regions Once a gene is
amplified, these amplified regions can be inserted into new
choromsome Lack a normal banding pattern and appear homogenous
(G-banded karyotype)
- Slide 44
- Slide 45
- Gene Amplification N-MYC ---- Neuroblastoma ERBB2 --- Breast
Cancers C-myc, L-myc, N-myc --- Small cell lung cancer **Greater
the amplification, poorer the prognosis
- Slide 46
- Epigenetic Changes Heritable changes in gene expression without
changing the DNA sequences Post-translational modfications of
histones + DNA methylation ===== Gene Expression Cancer cells ---
Hypermethylation within promoter regions and global DNA
Hypomethylation Tumor supressor genes --- hypermethlation ---
Silenced E.g. BRCA1, VHL, MLH1
- Slide 47
- Epigenetic Changes Genomic Imprinting: Maternal or paternal
allele of a gene or chromosome is modified by methylation and
inactivated
- Slide 48
- miRNAs Non-coding, single stranded RNA RNA-induced silencing
complex Post-transcriptional gene silencing Downregulate gene
expression by translational repression, and deadnylation In cancer
cells, increase oncogene expression or reduce tumor supression gene
expression
- Slide 49
- miRNAs 1. Reduced miRNA (Inhibitor of oncogene translation) ---
------------ Overproductin of oncogene 2. miRNA reduces tumor
supressor gene
- Slide 50
- Molecular Basis of Carcinogenesis
- Slide 51
- Carcinogenesis is MULTISTEP NO single oncogene causes cancer
BOTH several oncogenes AND several tumor suppressor genes must be
involved Gatekeeper/Caretaker concept Gatekeepers: ONCOGENES and
TUMOR SUPPRESSOR GENES Caretakers: DNA REPAIR GENES Tumor
PROGRESSION ANGIOGENESIS HETEROGENEITY from original single
cell
- Slide 52
- Cancer result from accumulation of multiple mutations
- Slide 53
- Chimney Sweeps ---------- Scrotal skin cancer
- Slide 54
- Two-stage experimental model (mouse skin) of cancer development
(Skin Cancer):- Initiation ---- Exposure of cells to a sufficient
dose of a carcinogenic agent (Initiator) Promoter ----- Induce
tumors in Initiated cells
- Slide 55
- Carcinogenesis: The USUAL (3) Suspects Initiation/Promotion
concept: BOTH initiators AND promotors are needed NEITHER can cause
cancer by itself INITIATORS (carcinogens) cause MUTATIONS PROMOTORS
are NOT carcinogenic by themselves, and MUST take effect AFTER
initiation, NOT before PROMOTERS enhance the proliferation of
initiated cells Promoters are non-tumorigenic by themselves
- Slide 56
- Initiators === Highly reactive electrophiles ( Electron
deficient) atoms Bind to nucleophiles ( Electron rich sites) in
cell E.g. DNA, RNA, Proteins
- Slide 57
- Slide 58
- Q: WHO are the usual suspects? Inflammation ? Teratogenesis ?
Immune Suppression? Neoplasia? Mutations?
- Slide 59
- A: The SAME 3 that are ALWAYS blamed! 1) Chemicals 2) Radiation
3) Infectious Pathogens
- Slide 60
- CHEMICAL CARCINOGENS: INITIATORS DIRECT -Propiolactone Dimeth.
sulfate Diepoxybutane Anticancer drugs (cyclophosphamide,
chlorambucil, nitrosoureas, and others) Acylating Agents
1-Acetyl-imidazole Dimethylcarbamyl chloride PROCARCINOGEN S
Polycyclic and Heterocyclic Aromatic Hydrocarbons Aromatic Amines,
Amides, Azo Dyes Natural Plant and Microbial Products Aflatoxin B1
Hepatomas Griseofulvin Antifungal Cycasin from cycads Safrole from
sassafras Betel nuts Oral SCC
- Slide 61
- CHEMICAL CARCINOGENS: INITIATORS OTHERS Nitrosamine and amides
(tar, nitrites) Vinyl chloride angiosarcoma in Kentucky Nickel
Chromium Insecticides Fungicides PolyChlorinated Biphenyls
(PCBs)
- Slide 62
- Cytochrome P450-dependent mono-xoygenase ----- Metabolizing
most carcinogens (E.g. Benzo [a]pyrene) ** Genes for these CP450
mono-oxygenase enzymes are polymorphic, determining susceptibility
to cancer E.g. CYP1A1 gene --- increases lung cancer in smokers
Carcinogen Aflatoxin B1 --- Mutation in p53 (transversion in codon
249 G:C T:A) or 249 (ser)
- Slide 63
- Nitrosamine in Food --Curing meat as a food preservation
Aflatoxin contamination
- Slide 64
- CHEMICAL CARCINOGENS: PROMOTORS HORMONES PHORBOL ESTERS (TPA),
activate kinase C PHENOLS DRUGS, many Initiated cells respond and
proliferate FASTER to promotors than normal cells
- Slide 65
- Following initiation, damaged dna template must be replicated
for the change to be heritable Promoter induction leads to
proliferation and clonal expansion of initiated cells
- Slide 66
- RADIATION CARCINOGENS UV: BCC, SCC, MM (i.e., all 3) IONIZING:
photons and particulate Hematopoetic and Thyroid (90%/15yrs) tumors
in fallout victims AML CML Solid tumors either less susceptible or
require a longer latency period than LEUK/LYMPH BCCs in Therapeutic
Radiation
- Slide 67
- Ultraviolet Rays UVA (320-400nm) UVB (280-320nm) -- Induction
of cutaneous cancers Pyrimidine dimers UVC (200-280nm) --- Filtered
by Ozone shield
- Slide 68
- VIRAL CARCINOGENESIS HPV SCC EBV Burkitt Lymphoma HBV
HepatoCellular Carcinoma (Hepatoma) HTLV1 T-Cell Malignancies KSHV
Kaposi Sarcoma
- Slide 69
- Oncogenic RNA Virus Human T-Cell Leukemia Virus Type 1:- T-cell
leukemia / lymphoma Target -- CD4+ Tcells Induction of
Leukemogenesis In addition to the genome gag, pol, env, another
type tax gene is crucial Tax --- Viral replication, viral mrna
transcription, transcription of host cell genes for T-cell
differentiation Tax protein inactivation of Inhibitor p16/INK4a,
allowing increased cyclin D cell cycle dysregulation Proliferating
T Cells --- Mutations and genomic instability
- Slide 70
- Slide 71
- Oncogenic DNA Virus Human Papilloma Virus DNA Virus ---- 70
different types of HPV Low Risk type (E.g. HPV 6 & 11) Benign
squamous papillomas ( Warts) E.g. Genital area Episomal form
(non-integrated) High Risk type (E.g. HPV 16, 18, 31) Squamous cell
carcinoma of cervix Integrated form Genomic instability
- Slide 72
- HPV Viral proteins HPV viral genes ---- E6 & E7 (oncogenic
potential) E7 --- Binds to RB---- E2F transcription factors
displaced Progress to cell cycle E7 --- Inactivates p21 inhibitor -
Increase cyclins E6 --- Binds and Degrades p53 & Bax Also
activates Telomerases Effects of E6 & E7 ---- Express oncogenic
proteins, inactivate tumor supressors, activate cyclins, inhibit
apoptosis, and combat cellular senescence
- Slide 73
- Epstein-Barr Virus Commonly found in HIV patients,
immunocompromised patients Central Africa B-lymphocyte infection by
its CD21 receptor (attachment) Latent infection, no viral
replication Hijaciking of normal signal pathways Borrows a normal
b- cell activation pathway Latent membane protein (LBP-1) and
EBNA-2 --- oncogenic --- B-cell proliferation ---inducing b-cell
lymphomas
- Slide 74
- Epstein-Barr Virus EBV virus -------------- Burkitt Lymphoma??
Repeated infections such as malaria----small number of EBV infected
B cells persist ----- Lymphomas ------ Translocation ===== >
c-myc oncogene
- Slide 75
- HBV & HCV Integration into host cell explained by
immunologic response --- chronic inflammation (proliferation of
hepatocytes, growth factors, chemokines, cytokines) Activation of
NF-kB, blocks apoptosis Productin of ROS (reactive oxygen species)
HBx gene found in HBV ----- activates transcription factors **NO
viral oncoproteins
- Slide 76
- H. Pylori Carcinogenesis Similar to HBV, HCV, chronic
inflammation such as epithelial cell proliferation leads to gastric
adenocarcinoma Chronic gastritis Gastric atrophy Intestinal
metaplasia Dysplasia Cancer CagA (cytotoxin-associated A) gene
Signaling cascade Gastric Lymphoma (B-cell type) 100% of gastric
lymphomas (i.e., M.A.L.T.-omas), mucosa-
associated-lymphoid-tissue, similar features of normal Peyers
patches Gastric CARCINOMAS also!
- Slide 77
- HOST DEFENSES IMMUNE SURVEILLENCE CONCEPT CD8+ T-Cells NK cells
MACROPHAGES ANTIBODIES
- Slide 78
- Escape from Immune Surveillance 1. Selective outgrowth Strong
immunogenic subclones are eliminated 2. Loss of expression of MHC
molecules 3. Lack of costimulation (modulate immune response by T
and B cells) 4. Immunosupression Chemicals, Radiation, tumor
products TGF-beta 5. Antigen masking Hidden antigens by glycocalyx
molecule 6. Apoptosis of cytotoxic T cells By expressing FasL on
T-lymphocytes
- Slide 79
- CYTOTOXIC CD8+ T-CELLS are the main eliminators of tumor
cells
- Slide 80
- How do tumor cells escape immune surveillance? Mutation, like
microbes MHC molecules on tumor cell surface Lack of CO-stimulation
molecules, e.g., (CD28, ICOS), not just Ag-Ab recognition
Immunosuppressive agents Antigen masking Apoptosis of cytotoxic
T-Cells (CD8), i.e., the damn tumor cell KILLS the T-cell!
- Slide 81
- Clinical Features of Neoplasia
- Slide 82
- Effects of TUMOR on the HOST Location anatomic ENCROACHMENT
HORMONE production Bleeding, Infection ACUTE symptoms, e.g.,
rupture, infarction METASTASES
- Slide 83
- Local / Hormonal Effects Location E.g. Pituitary Adenoma ---
Hypopituitarism Endocrine Gland Neoplasm -- Endocrine Insufficiency
GIT Neoplasm --- Obstruction, Intussception or Telescoping, melena,
hematuria Hormone Production Mostly benign Eg. Adenoma of
pancreatic islets (beta cell) Increased insulin --- Hypoglycemia
E.g. Non-endocrine tumors ----- Paraneoplastic syndrome
- Slide 84
- CACHEXIA Progressive body fat loss & lean muscle, along
with profound weakness, anorexia, and anemia **Food intake reduced,
however basal metabolic rate is increased --- Why?? Cytokines:- TNF
( by default) IL-(6) PIF (Proteolysis Inducing Factor)
- Slide 85
- Cancer Cachexia Progressive weakness, loss of appetite, anemia
and profound weight loss (>20%) Often correlates with tumor mass
& spread Etiology includes a generalized increase in metabolism
and central effects of tumor on hypothalamus Probably related to
macrophage production of TNF-a
- Slide 86
- Paraneoplastic Syndromes Group of signs and symptoms as a
result of substance produced by a tumor or reaction to a tumor Not
related to growth, spread or metastasis of the tumor itself
Earliest manifestation or appearance of the paraneoplastic syndrome
may precede the diagnosis and give clue to its presence Mimic
metastic disease
- Slide 87
- Paraneoplastic Syndromes Due to Products released by tumor
(Ectopic Hormone production) Cushings Syndrome Adrenal, Small Cell
Lung Ca ACTH (Increased Corticotropin and pro-opiomelanocortin,
POMC) Hypercalcemia Cancer osteolysis is the common cause either
due to primary bone or metastasis Humoral hypercalcemia --
Parathyroid hormone- related protein (PTHRP production) Breast
(PTHRP Osteolytic), Squamous cell bronchogenic carcinoma
- Slide 88
- Paraneoplastic Syndromes Neuromyopathic paraneoplastic
syndromes Myasthenia Gravis --- Bronchogenic, Breast ca (Antibodies
against tumor antigens) Inappropriate ADH syndrome (Hyponatremia)
Small cell lung ca Acanthosis Nigricans -- Hyperkeratosis of skin
Hypertrophic Osteoarthropathy Hypothalamic tumors (vasopressin)
Hypoglycemia - insulin or insulin like activities in Fibrosarcoma,
Cerebellar hemangioma. Vascular and Hematologic Manifestations --
Migratory thrombophlebitis (Trousseau syndrome) --- Pancreatic
Ca
- Slide 89
- PARA-Neoplastic Syndromes Nerve/Muscle, e.g., myasthenia w.
lung ca. Skin: e.g., acanthosis nigricans, dermatomyositis
Bone/Joint/Soft tissue: HPOA (Hypertrophic Pulmonary
OsteoArthropathy) Vascular: Trousseau, Endocarditis Hematologic:
Anemias Renal: e.g., Nephrotic Syndrome
- Slide 90
- ENDOCRINE Cushing syndromeSmall cell carcinoma of lungACTH or
ACTH-like substance Pancreatic carcinoma Neural tumors Syndrome of
inappropriate antidiuretic hormone secretion Small cell carcinoma
of lung; intracranial neoplasms Antidiuretic hormone or atrial
natriuretic hormones HypercalcemiaSquamous cell carcinoma of lung
Parathyroid hormone-related protein (PTHRP), TGF-, TNF, IL-1 Breast
carcinoma Renal carcinoma Adult T-cell leukemia/lymphoma Ovarian
carcinoma HypoglycemiaFibrosarcomaInsulin or insulin-like substance
Other mesenchymal sarcomas Hepatocellular carcinoma Carcinoid
syndromeBronchial adenoma (carcinoid)Serotonin, bradykinin
Pancreatic carcinoma Gastric carcinoma PolycythemiaRenal
carcinomaErythropoietin Cerebellar hemangioma Hepatocellular
carcinoma
- Slide 91
- Grading & Staging of Tumors Assess extent and spread of
neoplasm Making prognosis, and for treatment
- Slide 92
- GRADING/STAGING GRADING: HOW DIFFERENTIATED ARE THE CELLS?
STAGING: HOW MUCH ANATOMIC EXTENSION? TNM Which one of the above do
you think is more important?
- Slide 93
- Grading & Staging of Tumor Grading Cellular Differentiation
(Microscopic) Staging Progression or Spread (clinical)
- Slide 94
- Grading Degree of differentiation Number of mitoses
Architectural features Staging -------- TNM Size of lesion (T)
Extent of spread to lymph nodes (N) Presence or absence of
Metastases (M)
- Slide 95
- TNM : Staging of tumor:
- Slide 96
- WELL? (pearls) MODERATE? (intercellular bridges) POOR? (WTF!?!)
GRADING for Squamous Cell Carcinoma
- Slide 97
- ADENOCARCINOMA GRADING Lets have some FUN!
- Slide 98
- LABORATORY DIAGNOSIS 1. Excision / Biopsy 2. Fine needle
aspiration 3. Cytologic Smears
- Slide 99
- Excision:- Selection of area for excising large mass can be
challenging (center can be necrotic, periphery not reliable)
Preservation with caution --- Immersion in formalin Fixative for
Electron microscopy Refrigeration at optimal temperature for
molecular analysis
- Slide 100
- Fine needle aspiration:- Aspirating cells with small-bore
needle Cytologic examination of the smear Commonly breast, thyroid,
and lymph nodes Less Invasive and immediate need biopsies obtained,
BUT difficult Cytologic smears (PAP):- Smear, Fix, and Stain
Cervix, endometrial, bronchogenic, prostati for tumor cells in
abdominal, pleural joint and CSF Provides recognition of
differentiation to normal, dysplasia, malignant cells, cellular
changes specific to carcinoma in situ
- Slide 101
- IMMUNOHISTOCHEMISTRY Categorization of undifferentiated tumors
Antibodies specific to intermediate filaments 9E.g. cytokeratins,
desmin) Site of origin Organ-specific antigens E.g. PSA Prognostic
or therapeutic signficant molecules Receptors, e.g.,
Estrogen/progesterone receptors Protein products of oncogenes E.g.
ERBB2
- Slide 102
- Flow Cytometry:- Measure individual cell characteristics E.g.
DNA content of tumor cells T and B lymphocytes tumors Molecular
Diagnosis:- A) Diagnosis of NeoplasmsPolyclonal and monoclonal
proliferations of T or B Cells PCR FISH Hematopoietic neoplasms
(e.g. translocations) B) Prognosis of malignant neoplasms C)
Diagnosis of hereditary predisposition D) Detection of minimal
residual disease
- Slide 103
- TUMOR MARKERS CA-125 Ovarian cancer CEA (carcinoembryonic
antigen) colon, pancreas, lung, stomach AFP (alpha-fetoprotein)
Hepatocellular carcinoma, germ cell tumors, yolk sac tumors
Beta-HCG - Chorioncarcinoma
- Slide 104
- Slide 105
- Slide 106
- Slide 107
- Slide 108
- Slide 109
- Slide 110
- Slide 111
- Slide 112
- Slide 113
- Slide 114
- Slide 115
- Slide 116
- Slide 117
- Slide 118
- Slide 119
- Slide 120
- Slide 121
- Slide 122